Genocea is a biopharmaceutical company developing neoantigen cancer immunotherapies. We are unique: we identify new targets, or neoantigens, specific to individuals, based on each person’s actual CD4⁺ and CD8⁺ T cell responses, rather than relying on poorly predictive in silico methods.
Our proprietary and proven ATLAS technology platform allows for both the identification and ex vivo characterization of patient neoantigens. By selecting only empirically confirmed neoantigens of CD4⁺ and CD8⁺ anti-tumor immune response, and ruling out “inhibitory” neoantigens, we believe we can create best-in-class immunotherapies.
Our lead vaccine program, GEN-009, is being evaluated in a Phase 1/2a clinical trial across a variety of cancer types.